Colon Cancer (Stage II &Amp;Amp; III)
Conditions
Keywords
renin-angiotensin system inhibitor, colon cancer, disease-free survival
Brief summary
The goal of this retrospective cohort study is to learn about the long-term effects of renin-angiotensin system inhibitors (RASi) in preventing patients with hypertension and stage II/III colon cancer from recurrence and metastases after radical resection. The main question it aims to answer is: Does RASi improve the 3-year disease-free survival of patients with hypertension and stage II/III colon cancer after surgery? Participants with hypertension and already having radical resection of stage II/III colon cancer will be followed up for 3 years.
Detailed description
Previous studies have shown that renin-angiotensin system inhibitors (RASi) may reduce postoperative recurrence and metastases of colorectal cancer. However, the relevant clinical evidences were low level and controversial. This study retrospectively collect patients with hypertension and stage II/III colon cancer after radical resection, and compare the patients with vs. without RASi in terms of long-term oncological outcomes, to study the inhibitory effect of RASi on recurrence and metastasis.
Interventions
DRUGRenin-angiotensin system inhibitors (RASi)
Using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or inappropriate use of RASi.
DRUGNo renin-angiotensin system inhibitors (No RASi)
Not using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or needing RASi.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Inferior tumor edge \> 15 cm from anal verge; 2. Received radical resection of primary tumor; 3. Pathological proved stage II or stage III adenocarcinoma; 4. No evidence of distant metastases at time of surgery (including pelvis, peritoneum, liver, lung, brain, bone, distant lymph node, etc), according to ultrasound, CT, MRI, PET-CT, intraoperative exploration, etc; 5. Combined with hypertension at time of surgery; 6. No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri; 7. Informed consent.
Exclusion criteria
1. Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc; 2. Multiple primary colorectal cancer; 3. Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.); 4. Co-existent inflammatory bowel disease; 5. Pregnancy or lactation; 6. Received any of preoperative anti-cancer treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year disease-free survival | 3 years after surgery | The events of 3-year disease-free survival are defined as any recurrence of metastases or death within 3 years after surgery. |
Other
| Measure | Time frame | Description |
|---|---|---|
| 3-year overall survival | 3 years after surgery | The events of 3-year overall survival are defined as any death within 3 years after surgery. |
Countries
China
Outcome results
None listed